Harshitha Dudipala | Cancer Genetics | Research Excellence Award

Published on by Genetics and Genomics

Dr. Harshitha Dudipala | Cancer Genetics | Research Excellence Award

University of California San Diego | United States

Dr. Harshitha R. Dudipala, MD, is a board-certified physician in Internal Medicine and a highly accomplished Hematology & Oncology Fellow at the University of California, San Diego (Moores Cancer Center), with fellowship completion expected. She completed her Internal Medicine residency at Boston University Medical Center and earned her MD from Northeast Ohio Medical University, following a BS in Natural Sciences from the University of Akron. Dr. Dudipala has an extensive research portfolio spanning genitourinary oncology, lung cancer, immunotherapy biomarkers, molecular profiling, health disparities, and quality improvement, with multiple peer-reviewed publications in high-impact journals and presentations at ASCO, EACR, AAMC, and AMA. Her work has been featured in ASCO Daily News, and she has received numerous honors, including the Alice Jacobs Citizenship Award. An active leader and educator, she holds key roles in fellowship wellness, women in medicine, medical education, advocacy, and community health, reflecting a career dedicated to academic excellence, equity in cancer care, and physician leadership.

Citation Metrics (Scopus)

40
30
20
10
  0

Citations
25

Documents
9

h-index
4

Citations

Documents

h-index


View Scopus Profile
 View Orcid Profile

Featured Publications

Leilei Wu | Lung Cancer | Best Researcher Award

Published on by Genetics and Genomics

Dr. Leilei Wu | Lung Cancer | Best Researcher Award

Zhejiang Cancer Hospital | China

Author Profile

Scopus

Orcid ID

📘 BIOGRAPHY OF DR. LEILEI WU

🎓 EARLY ACADEMIC PURSUITS

Dr. Leilei Wu laid the groundwork for his exceptional career by pursuing an M.D. and Ph.D., focusing his academic efforts on advancing knowledge in thoracic surgery. During his formative years, he displayed a strong dedication to understanding the complexities of lung cancer and esophageal cancer, particularly their diagnosis and treatment.

🏥 PROFESSIONAL ENDEAVORS

As a member of the Department of Thoracic Surgery at Zhejiang Cancer Hospital, Hangzhou, Dr. Wu has combined surgical expertise with groundbreaking research. He is actively involved in clinical and translational studies, making substantial contributions to advancing thoracic surgery techniques and treatment protocols for lung and esophageal cancer.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON LUNG CANCER

Dr. Wu's research focuses on innovative treatment strategies for thoracic malignancies. His contributions include:

  1. Exploring the synergy of AMG-510 with cisplatin for increased antitumor effects in KRAS G12C mutant lung adenocarcinoma.
  2. Studying the prognosis and risks of diabetes mellitus post-lung transplantation, offering critical insights into patient care.
  3. Investigating the compound Osalmid for its dual effects in inhibiting lung adenocarcinoma progression and enhancing EGFR-TKI therapy sensitivity.

🌍 IMPACT AND INFLUENCE

Dr. Wu's research has gained international recognition through prestigious conferences:

  • Poster Presentation: 31st European Conference on General Thoracic Surgery, Milano, Italy (2023)
    • “AMG-510 and Cisplatin Combination Increases Antitumor Effect in Lung Adenocarcinoma with KRAS G12C Mutation.”
  • Oral Presentation: 31st European Conference on General Thoracic Surgery, Milano, Italy (2023)
    • “Prognosis and Risk of Diabetes Mellitus in Patients After Lung Transplantation.”
  • Poster Presentation: IASLC World Conference on Lung Cancer, San Diego, USA (2024)
    • “Osalmid Inhibits Lung Adenocarcinoma Progression and Sensitizes to EGFR-TKIs: A Preclinical Study.”

📈 ACADEMIC CITES AND RECOGNITION

Dr. Wu's innovative work has garnered significant attention from peers, highlighting his commitment to excellence. His contributions to thoracic oncology are cited frequently, reflecting the relevance and influence of his research in the scientific community.

🏅 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Wu aims to further transform thoracic oncology by:

  • Developing precision medicine techniques tailored to individual genetic profiles.
  • Refining minimally invasive surgical methods.
  • Mentoring the next generation of thoracic surgeons and researchers.

His dedication to bridging the gap between clinical practice and scientific discovery ensures a lasting impact on thoracic surgery and oncology worldwide.

🔑 KEYWORDS

Thoracic Surgery, Lung Cancer, Esophageal Cancer, Translational Research, AMG-510, Cisplatin, KRAS G12C Mutation, Osalmid, EGFR-TKI Sensitivity, Zhejiang Cancer Hospital, Thoracic Oncology Innovation.

📑NOTABLE PUBLICATIONS 

"The association between the cough and the inflation of esophagus" 

  • Authors: Wu, L.-L. , Xie, D.
  • Journal: Respiratory Investigation
  • Year: 2024

"Apoptosis and cuproptosis Co-activated Copper-based metal-organic frameworks for cancer therapy" 

  • Authors: Li, K. , Wu, L. , Wang, H. , Wang, J. , Xie, D.
  • Journal: Journal of Nanobiotechnology
  • Year: 2024

"The molecular characteristics could supplement the staging system of pT2/T3N0M0 esophageal squamous cell carcinoma: a translational study based on a cohort with over 20 years of follow-up" 

  • Authors: Jiang, W.-M. , Tian, J.-Y. , Guo, Y.-H. , Wu, L.-L. , Ma, G.-W.
  • Journal: Cancer Cell International
  • Year: 2024

"Longitudinal assessment of quality of life indicators and prognosis in esophageal cancer patients with curative resection" 

  • Authors: Qiu, L.-H. , Liang, S.-H. , Wu, L. , Zhong, J.-D. , Ma, G.-W.
  • Journal: Journal of Thoracic Disease
  • Year: 2024

"Antitumor effects of a Sb-rich polyoxometalate on non-small-cell lung cancer by inducing ferroptosis and apoptosis" 

  • Authors: Lin, J.-W. , Zhou, Y. , Xiao, H.-P. , Li, X.-X. , Li, Z.-X.
  • Journal: Chemical Science
  • Year: 2024